Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to shield kidney transplant patients from deadly infections

NCT ID NCT07407673

First seen Feb 12, 2026 · Last updated May 24, 2026 · Updated 20 times

Summary

This study tests whether a daily antibiotic (pivmecillinam) can prevent serious bloodstream infections in 150 kidney transplant recipients who are at high risk. Participants will receive either the antibiotic or a placebo for six months after their transplant. The goal is to reduce infections, hospital stays, and improve quality of life without harming the gut bacteria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aarhus University Hospital

    Aarhus, Denmark

    Contact

  • Odense University Hospital

    Odense, Denmark

    Contact

  • Rigshospitalet

    Copenhagen, 2100, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.